Bio-Rad (BIO) Hits a New 52-Week High: What's Driving It?
Zacks Investment Research | Aug 16, 2021 10:30PM ET
Bio-Rad Laboratories (NYSE:BIO), Inc. industry it belongs to and 33.7% surge of the S&P 500 composite.
Over the past five years, the company registered earnings growth of 23.6% which is way ahead of the industry’s 5.8% rise and the S&P 500’s 2.8% increase.
At present, Bio-Rad operates under two business segments: Life Science and Clinical Diagnostics. The company delivered solid top-and bottom-line growth in the second quarter of 2021. The company witnessed strong constant currency and year-over-year revenue growth across both its reporting segments. The uptick in the Clinical Diagnostics arm driven by the ongoing recovery across product lines in all regions during the reported quarter is encouraging as well. A strong solvency position bodes well for the stock.
Image Source: Zacks Investment Research
Let’s delve deeper.
h3 Key Drivers/h3Q2 Upsides: Bio-Rad exited the second quarter of 2021 on an extremely bullish note with better-than-expected revenues and earnings. Its second-quarter 2021 earnings beat the Zacks Consensus Estimate by 86.3%. The company witnessed solid top-and bottom-line growth in the quarter under review. The strong constant currency and year-over-year revenue growth across both of its operating segments contributed to the top-line growth. Expansion of operating margin buoys optimism for the stock. The raised 2021 revenue guidance is indicative of continuation of this bullish trend.
Segmental Growth: The market is upbeat about Bio-Rad’s impressive segmental performance in the second quarter of 2021.The company’s Life Science segment witnessed sales growth of 32.6% at CER and reported growth of 27.1%. Growth at CER was primarily driven by rise in demand for qPCR, Western Blotting, Droplet Digital PCR and Process Media products. The company witnessed strong growth in the biopharma market for the Droplet Digital PCR platform along with a healthy uptake for ddPCR in wastewater solutions. Further, Bio-Rad’s Clinical diagnostics segment grew 28% at CER and 34.3% on a reported basis driven by recovery in routine testing.
Clinical Diagnostics Continues to Gain Momentum: Bio-Rad’s clinical diagnostics arm registered double-digit growth across all product lines in the second quarter of 2021. In a geographic basis, the diagnostics group’s currency-neutral year-over-year sales grew across all regions. We are optimistic about the company’s recent partnership with Seegene to provide diagnostic testing products to U.S. markets. Other notable launches in this segment include the PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit to detect SARS-CoV-2 in a community’s wastewater, molecular qPCR and ddPCR instruments and assays, antibody tests, quality controls, and ddPCR assays to detect SARS-CoV-2 variants of concern.
Strong Solvency: Bio-Rad exited the second quarter of 2021 with cash, cash equivalents and short-term investments of $1.17 billion compared with $1.02 billion at the end of first-quarter 2021. Meanwhile, total debt (including current maturities) at the end of the second quarter was $12.5 million. This figure is much lower than the quarter-end cash and cash equivalent, and investments level, indicating good news in terms of solvency position, especially during the year of economic downturn. This implies that the company is holding sufficient cash for debt repayment.
h3 Downsides/h3Economic Uncertainty: Bio-Rad’s business is largely dependent on global economic conditions. The company is exposed to the risk of a slowdown in China economy along with some other emerging markets, particularly the oil-producing nations. The company is also closely monitoring the potential adverse impacts on its business following the U.K.'s decision to exit the European Union. Further, macroeconomic woes stemming from the coronavirus pandemic are other concerns for the company.
Difficult Pricing Scenario: Bio-Rad is exposed to the effects of changes in the healthcare industry in the United States and Europe. The changing trend toward managed care, healthcare reform of the delivery system in the United States, efforts to reform in Europe along with increasing consolidations among healthcare providers have resulted in increased pricing burden.
h3 Zacks Rank and Other Key Picks/h3Currently, Bio-Rad carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks from the Medical-Products industry include VAREX IMAGING
Envista Holdings, sporting a Zacks Rank #2, has a long-term earnings growth rate of 26.8%.
BellRing Brands, carrying a Zacks Rank #2, has a long-term earnings growth rate of 25.3%.
Get The News You Want
Zacks' Top Picks to Cash in on Artificial Intelligence
In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.
See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.